Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.53−0.24 (-1.62%)
Close on Nov 18, 2026Market cap $1.53BP/E –Yield –
Sarepta Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Sarepta Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $81.85M. For fiscal 2025 it was -$307.45M. The highest annual figure on record is $25.26M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$307.45M | – |
| FY2024 | Dec 31, 2024 | -$342.74M | – |
| FY2023 | Dec 31, 2023 | -$577.10M | – |
| FY2022 | Dec 31, 2022 | -$356.17M | – |
| FY2021 | Dec 31, 2021 | -$481.66M | -2006.5% |
| FY2020 | Dec 31, 2020 | $25.26M | – |
| FY2019 | Dec 31, 2019 | -$516.09M | – |
| FY2018 | Dec 31, 2018 | -$449.82M | – |
| FY2017 | Dec 31, 2017 | -$244.00M | – |
| FY2016 | Dec 31, 2016 | -$251.16M | – |
| FY2015 | Dec 31, 2015 | -$152.87M | – |
| FY2014 | Dec 31, 2014 | -$153.98M | – |
| FY2013 | Dec 31, 2013 | -$67.07M | – |
| FY2012 | Dec 31, 2012 | -$29.80M | – |
| FY2011 | Dec 31, 2011 | -$24.86M | – |
| FY2010 | Dec 31, 2010 | -$16.04M | – |
| FY2009 | Dec 31, 2009 | -$9.73M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $196.52M | -14.4% |
| Q1 FY2026 | Mar 31, 2026 | -$204.76M | – |
| Q4 FY2025 | Dec 31, 2025 | $127.62M | +136.5% |
| Q3 FY2025 | Sep 30, 2025 | -$37.52M | – |
| Q2 FY2025 | Jun 30, 2025 | $229.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$627.09M | – |
| Q4 FY2024 | Dec 31, 2024 | $53.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$107.96M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$274.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$73.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$144.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$140.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$218.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$100.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$73.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$75.89M | – |
| Q1 FY2022 | Mar 31, 2022 | -$106.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.53M | – |
| Q3 FY2021 | Sep 30, 2021 | -$133.57M | – |
| Q2 FY2021 | Jun 30, 2021 | -$115.04M | – |
| Q1 FY2021 | Mar 31, 2021 | -$201.52M | -132.6% |
| Q4 FY2020 | Dec 31, 2020 | -$203.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$263.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$126.77M | – |
| Q1 FY2020 | Mar 31, 2020 | $618.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$181.05M | – |
| Q3 FY2019 | Sep 30, 2019 | -$76.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$95.69M | – |
| Q1 FY2019 | Mar 31, 2019 | -$162.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$142.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$133.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$125.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -$47.83M | – |
| Q4 FY2017 | Dec 31, 2017 | -$34.96M | – |
| Q3 FY2017 | Sep 30, 2017 | -$58.67M | – |
| Q2 FY2017 | Jun 30, 2017 | -$88.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$62.35M | – |
| Q4 FY2016 | Dec 31, 2016 | -$84.15M | – |
| Q3 FY2016 | Sep 30, 2016 | -$61.46M | – |
See a number that looks wrong?